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Abstract
Introduction: Whether low socioeconomic status (SES) is associated with worse rheumatoid arthritis (RA) outcomes
in countries with general tax-financed healthcare systems (such as Sweden) remains to be elucidated. Our aim was
to investigate the influence of educational background (achieving university/college degree (high) or not (low)) on
the outcomes of early RA, in terms of disease activity (DAS28), pain (VAS-pain), and functional impairment (HAQ).
Methods: We evaluated DMARD-naïve RA patients recruited in the Epidemiological Investigation of RA (EIRA) study
with outcomes followed in the Swedish Rheumatology Quality (SRQ) register (N = 3021). Outcomes were
categorized in three ways: 1) scores equal to/above median vs. below median; 2) DAS28-based low disease activity,
good response, remission; 3) scores decreased over the median vs. less than median. Associations between
educational background and outcomes were calculated by modified Poisson regressions, at diagnosis and at each
of the three standard (3, 6, 12 months) follow-up visits.
Results: Patients with different educational background had similar symptom durations (195 days) and anti-
rheumatic therapies at baseline, and comparable treatment patterns during follow-up. Patients with a high
education level had significantly less pain and less functional disability at baseline and throughout the whole
follow-up period (VAS-pain: baseline: 49 (28-67) vs. 53 (33-71), p <0.0001; 1-year visit: RR = 0.81 (95 % CI 0.73-0.90).
HAQ: baseline: 0.88 (0.50-1.38) vs. 1.00 (0.63-1.50), p = 0.001; 1-year visit: 0.84 (0.77-0.92)). They also had greater
chances to achieve pain remission (VAS-pain ≤20) after one year (1.17 (1.07-1.28)). Adjustments for smoking and BMI
altered the results only marginally. Educational background did not influence DAS28-based outcomes.
Conclusion: In Sweden, with tax-financed, generally accessible healthcare system, RA patients with a high
education level experienced less pain and less functional disability. Further, these patients achieved pain remission
more often during the first year receiving standard care. Importantly, education background affected neither time
to referral to rheumatologists, disease activity nor anti-rheumatic treatments.
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Introduction
Low socioeconomic status (SES), measured in a variety
of ways (e.g., formal educational background, occupa-
tion, household income, ethnicity), has been associated
with an increased risk of rheumatoid arthritis (RA), and
a worse disease outcome [1, 2]. Despite several reports
describing the adverse link between deprivation and
prognosis [3–11], a majority of the reported studies had
a cross-sectional design lacking subsequent follow up
[3–6], whereas the existing longitudinal studies have fo-
cused mainly on long-term consequences (>2 years from
baseline) [7–11]. In none of the previous studies has
there been the opportunity to analyze the contribution
of other known determinants such as the use of anti-
rheumatic therapy, or smoking, on RA outcomes. Add-
itionally, whether low SES is associated with worse RA
outcomes in countries with general tax-financed health-
care systems (such as Sweden) remains to be elucidated.
Our aim was to evaluate whether SES, here measured as
formal educational background, affects the chance of good
control of RA during the first year in patients receiving
standard care in Sweden. We used data from a well-
established population-based RA cohort that has included
incident cases captured before the initiation of the first
disease-modifying anti-rheumatic drug (DMARD).
Methods
Study population
The study participants were newly diagnosed, DMARD-
naive RA patients from the Epidemiological investigation
of rheumatoid arthritis (EIRA) study in Sweden (previ-
ously described in detail [12]), who were included during
1996–2011, and who had clinical follow-up data from
the Swedish Rheumatology Quality (SRQ) register until
2013. In total, 3,021 (92 %) of all EIRA cases were in-
cluded. We excluded: EIRA patients not reported to
SRQ, or despite being reported to SRQ, lacking informa-
tion on all outcome variables (n = 254); patients with
symptom duration longer than one year (n = 18); and
one patient who lacked information on educational
background. All participants gave informed consent and
the study was approved by the ethical review board at
Karolinska Institutet.
Definition of education and potential confounders
Information on exposure (formal educational background)
and several confounders (e.g., age at diagnosis, sex, smok-
ing, alcohol consumption, body mass index (BMI), etc.)
was collected through a self-administrated questionnaire
(from the EIRA study) at baseline. Briefly, age at diagnosis
was a continuous variable. Ever smokers were defined as
current and former cigarette smokers while never smokers
reported they had never smoked. Pack-years of smoking
were calculated with one pack-year equivalent to smoking
20 cigarettes per day for one year. Ever drinking was cap-
tured by questions about present alcohol consumption
and previous habitual consumption, and included both
current and former drinkers. Total alcohol consumption
was measured in drinks per week (1 drink = 16 g alcohol).
BMI was calculated from self-reported height and weight
(kg/m2). Formal educational background at diagnosis was
categorized as having a university/college degree (high
level of education) versus no university/college degree
(low level of education). Several potential determinants of
outcomes, including time to the first encounter with a
rheumatologist, severity of disease at baseline, first and
subsequent use of anti-rheumatic therapy, were recorded
by rheumatologists and were accessible through SQR.
Outcome measures
Three clinical aspects were considered as outcome mea-
sures: the 28-joint disease activity score (DAS28), visual
analog scale for pain (VAS-pain, range 0–100), and
health assessment questionnaire (HAQ) score (range 0–3).
Please note that in all measures, a higher score represents a
poorer outcome.
We primarily classified all outcome measures into
equal to/above median versus below median. We further
separately categorized patients based on achievement
(yes/no) of low disease activity (DAS28 ≤3.2), good re-
sponse (DAS28 ≤3.2 and DAS28 decrease >1.2) and re-
mission (DAS28 ≤2.6) according to European League
Against Rheumatism (EULAR)/American College of
Rheumatology (ACR) recommendations [13] and defined
pain remission as ≤20 mm on a 100-mm VAS [14]. We
further looked into the decrease (scores from each visit
compared to the baseline level) larger than the median
decrease in all outcome measures. We also investigated
the influence of educational background on each com-
ponent of the DAS28 (i.e., the number of tender and
swollen joints out of 28 joints, the erythrocyte sedimen-
tation rate (ESR), and the patient’s global assessment of
general health).
Statistical analysis
We used modified Poisson regression to obtain the risk
ratio (RR) with 95 % confidence interval (CI) of the out-
comes associated with educational background [15]. Pa-
tients with university/college degree (high level of
education, exposed) were compared with patients with-
out (low level of education, unexposed), at each time
point, i.e., the first three follow-up visits (3 (2.5–5.0), 6
(5.0–7.5), and 12 (7.5–18.0) months) after diagnosis.
All analyses were adjusted for potential confounders,
i.e., age at diagnosis (continuous, fitted in both the linear
and squared term in the model), sex (binary), pack-years
of cigarettes smoking (continuous), total alcohol as-
sumption (continuous), BMI (continuous), and outcome
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Total Chi square statistics,
p values
A: Basic characteristics number (%) number (%) number (%)
Sex
Female 586 (82.4) 1585 (68.6) 2171 (71.9) 51.2, <0.0001
Male 125 (17.6) 725 (31.4) 850 (28.1)
Age (years) at diagnosis
<40 164 (23.1) 410 (17.8) 574 (19.0) 44.6, <0.0001
40–50 160 (22.5) 370 (16.0) 530 (17.5)
50–60 215 (30.2) 694 (30.0) 909 (30.1)
60–70 172 (24.2) 836 (36.2) 1008 (33.4)
Median 51.0 52.4 54.5
Treatment initiated at the diagnosis
DMARDs (including MTX) 606 (85.2) 2004 (86.8) 2610 (86.4) 1.1, 0.30
Biologics 32 (4.5) 145 (6.3) 177 (5.9) 3.1, 0.08
Cortisone 276 (38.8) 946 (41.0) 1223 (40.5) 1.0, 0.32
NSAIDs 384 (54.0) 1153 (49.9) 1537 (50.9) 0.6, 0.06
ACPA status
Present 458 (65.2) 1521 (66.8) 1979 (66.4) 0.6, 0.44
Absent 245 (34.8) 757 (33.2) 1002 (33.6)
Cigarette smoking
Never 297 (41.8) 674 (29.3) 971 (32.4) 76.0, <0.0001
Past smokers 216 (30.5) 701 (30.5) 917 (30.4)
Current smokers 106 (14.9) 682 (29.7) 788 (26.2)
Non regular smokers 91 (12.8) 242 (10.5) 333 (11.0)
Alcohol consumption
Never drinkers 49 (6.9) 266 (11.5) 315 (10.4) 12.5, 0.0004
Ever drinkers 662 (93.1) 2041 (88.5) 2703 (89.6)
BMI
Normal weight: BMI <25 445 (63.9) 1103 (48.6) 1548 (52.2) 51.1, <0.0001
Overweight: BMI 25–30 189 (27.1) 821 (36.2) 1010 (34.1)
Obese: BMI >30 63 (9.0) 344 (15.2) 407 (13.7)
Median 23.7 25.1 24.8
Physical activity before diagnosis
Sedentary/moderate exercise 518 (73.0) 1513 (65.8) 2031 (67.5) 12.7, 0.0004
Regular exercise/work out 192 (27.0) 787 (34.2) 979 (32.5)
B: Outcome measures Median (IQR) Median (IQR) Median (IQR) P values (Wilcoxon test)
DAS28 at diagnosis 5.23 (4.26 to 6.05) 5.21 (4.32 to 6.07) 5.22 (4.30 to 6.06) 0.93
VAS-pain at diagnosis 49 (28 to 67) 53 (33 to 71) 51 (32 to 70) <0.0001
HAQ at diagnosis 0.88 (0.50 to 1.38) 1.00 (0.63 to 1.50) 1.00 (0.63 to 1.38) 0.001
DAS28 change at 3-month visit –1.69 (–2.80 to –0.72) –1.63 (–2.72 to –0.62) –1.65 (–2.74 to –0.63) 0.19
VAS-pain change at 3-month visit –17 (–40 to –2) –20 (–43 to –1) –19 (–42 to –1) 0.69
HAQ change at 3-month visit –0.38 (–0.75 to 0.00) –0.37 (–0.75 to 0.00) –0.37 (–0.75 to 0.00) 0.28
DAS28 change at 6-month visit –2.19 (–3.13 to –1.01) –2.02 (–3.06 to –0.91) –2.05 (–3.08 to –0.93) 0.19
VAS-pain change at 6-month visit –20 (–41 to –2) –21 (–43 to –1) –21 (–42 to –1) 0.94
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measure at baseline (e.g., when analyzing DAS-28-related
outcomes at each of the three follow-up visits, we also
adjusted for DAS28 baseline level. The same strategy was
applied for the HAQ and VAS-pain). In addition, we
performed analysis with additional adjustments for resi-
dential area (county), leisure time physical activity, anti-
citrullinated protein/peptide antibodies (ACPA)-status,
treatment at baseline, and study phase. We subsequently
carried out stratified analysis based on ACPA status
(ACPA-positive and ACPA-negative subgroups), and
treatment (DMARDs and other treatments). All analyses
were performed in SAS V.9.3.
Results
Basic characteristics of the patients are shown in
Table 1. In total, 72 % of the cases were female, and 66
% were ACPA-positive. The RA patients with a low
level of education were slightly older, comprised more
male patients, and were more likely to be smokers,
overweight, and have a less sedentary lifestyle as com-
pared with university-educated patients; whereas in
terms of ACPA status, no differences were observed be-
tween the two groups. In addition, the median symp-
tom duration was 195 days, exactly the same for both
groups of patients.
DAS28-based outcome measures showed comparable
baseline levels between the exposed (patients with a uni-
versity education) and unexposed (patients without a
university education) groups but for VAS-pain and
HAQ, slightly, although statistically significantly lower,
median levels were observed among patients with a uni-
versity education (VAS-pain 49 (28–67) vs. 53 (33–71),
p value <0.0001, HAQ 0.88 (0.50–1.38) vs. 1.00 (0.63–
1.50), p value = 0.001). We observed no significant
Table 1 Baseline characteristics of patients included in the study, N = 3021 (Continued)
HAQ change at 6-month visit –0.50 (–0.88 to –0.12) –0.38 (–0.87 to 0.00) –0.38 (–0.87 to 0.00) 0.19
DAS28 change at 1-year visit –2.37 (–3.40 to –1.28) –2.16 (–3.30 to –0.96) –2.21 (–3.32 to –1.03) 0.02
VAS-pain change at 1-year visit –20 (–42 to –5) –22 (–43 to 0) –21 (–43 to –1) 0.72
HAQ change at 1-year visit –0.50 (–0.88 to –0.13) –0.38 (–0.88 to 0.00) –0.38 (–0.88 to 0.00) 0.02
DMARD disease-modifying anti-rheumatic drug, MTX methotrexate, NSAID non-steroidal anti-inflammatory drug, ACPA anti-citrullinated protein/peptide antibodies,
BMI body mass index, DAS28 disease activity in 28 joints, VAS visual analog scale, HAQ health assessment questionnaire
Table 2 Prescription of anti-rheumatic therapy among patients with different levels of education
Treatment Without degree, number (%) With degree, number (%) Crude p values, from Chi square test Adjusted p values*
Treatment initiated at the diagnosis (baseline)
DMARDs 2004 (86.8) 606 (85.2) 0.30 0.44
NSAIDs 1153 (49.9) 384 (54.0) 0.06 0.10
Cortisone 946 (41.0) 276 (38.8) 0.32 0.69
Biologics 145 (6.3) 32 (4.5) 0.08 0.08
3-month visit
DMARDs 1642 (90.7) 518 (89.8) 0.52 0.59
NSAIDs 699 (38.6) 241 (41.8) 0.17 0.10
Cortisone 736 (40.6) 242 (41.9) 0.58 0.47
Biologics 186 (10.3) 52 (9.0) 0.38 0.27
6-month visit
DMARDs 1435 (90.4) 409 (90.3) 0.93 0.56
NSAIDs 558 (35.2) 165 (36.4) 0.62 0.26
Cortisone 606 (38.2) 173 (38.2) 0.99 0.89
Biologics 203 (12.8) 56 (12.4) 0.81 0.42
1-year visit
DMARDs 1807 (87.7) 553 (87.5) 0.91 0.33
NSAIDs 660 (32.0) 190 (30.1) 0.35 0.82
Cortisone 711 (34.5) 223 (35.3) 0.72 0.86
Biologics 357 (17.3) 120 (19.0) 0.34 0.65
*P values were adjusted for age at diagnosis, gender, alcohol assumption, pack-years of smoking, body mass index, and baseline outcome values. DMARDs
disease-modifying anti-rheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs
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differences in anti-rheumatic treatments initiated at base-
line or during the first year of disease (Table 2).
Risk ratios for outcome measures equal to/above median
Throughout the follow-up period, patients with a high
level of education had a decreased risk of having VAS-
pain above the median compared with patients with a
low level of education (RR (95 % CI) for the 3-month
visit 0.82 (0.74–0.91); 6-month visit 0.86 (0.77–0.96); 1-
year visit 0.81 (0.73–0.90)). They also had less functional
impairment than patients with a low level of education
(HAQ, 3-month visit 0.83 (0.75–0.91); 6-month visit
0.87 (0.78–0.97); 1-year visit 0.84 (0.77–0.92)) (Table 3).
For both VAS-pain and HAQ, the results at the 3-month
and 1-year visits remained significant after adjustment.
No significant associations were identified between edu-
cational background and DAS28.
Risk ratios for DAS28 remission, VAS-pain remission
We observed no associations between educational back-
ground and DAS28 remission, low disease activity or
good response, except for good response at the 1-year
visit (1.10 (1.01–1.20); this did not remain significant
after adjustment for potential confounders) and for re-
mission at the 1-year visit (1.12 (1.02–1.24)). Neither did
we observe any significant associations for DAS28 com-
ponents (ESR, C-reactive protein (CRP), and patient glo-
bal assessment) in relation to educational background
(data not shown). Higher education was associated with
15–25 % greater chance of achieving VAS-pain remis-
sion (3-month visit: 1.25 (1.13–1.38); 6-month visit: 1.14
(1.02–1.28); 1-year visit: 1.17 (1.07–1.28)). The results,
however, did not remain significant at the 6-month visit
after adjustment (Table 4).
Risk ratios for outcome measures decrease over the
median
Higher education was not associated with increased
chance of improvement (more than the median) in VAS-
pain (Table 4). Thus, patients with a university education
had less pain at baseline and had equivalent decrease to
patients without, leading to better pain outcomes at follow
up. For HAQ, patients with a university education had a
greater chance of improvement in physical function at the
1-year visit (1.11(1.02–1.20)); after adjustment the result
was also significant at the 3-month visit (1.11 (1.02–1.21)).
Table 3 Risk ratios and 95 % confidence intervals for the association between educational level and having outcome measures of
rheumatoid arthritis above the median
Visits University/college
degree
Outcome values above the median
No Yes Risk ratio, crude (95 % CI) Risk ratio* (95 % CI)
DAS28
3 months No 860 (74.7) 291 (25.3) 1.0 ref. 1.0 ref.
Yes 889 (76.6) 272 (23.4) 0.95 (0.86 to 1.05) 0.99 (0.90 to 1.09)
6 months No 762 (77.0) 227 (23.0) 1.0 ref. 1.0 ref.
Yes 776 (78.4) 214 (21.6) 0.96 (0.86 to 1.07) 1.01 (0.90 to 1.13)
1 year No 975 (75.6) 314 (24.4) 1.0 ref. 1.0 ref.
Yes 1007 (77.4) 294 (22.6) 0.95 (0.87 to 1.04) 0.98 (0.89 to 1.08)
VAS-pain
3 months No 817 (72.1) 316 (27.9) 1.0 ref. 1.0 ref.
Yes 948 (79.3) 247 (20.7) 0.82 (0.74 to 0.91) 0.88 (0.79 to 0.98)
6 months No 751 (75.3) 246 (24.7) 1.0 ref. 1.0 ref.
Yes 804 (80.3) 197 (19.7) 0.86 (0.77 to 0.96) 0.93 (0.82 to 1.05)
1 year No 947 (72.9) 352 (27.1) 1.0 ref. 1.0 ref.
Yes 1058 (80.0) 264 (20.0) 0.81 (0.73 to 0.90) 0.85 (0.76 to 0.94)
HAQ
3 months No 743 (71.8) 292 (28.2) 1.0 ref. 1.0 ref.
Yes 986 (79.1) 261 (20.9) 0.83 (0.75 to 0.91) 0.90 (0.82 to 0.99)
6 months No 689 (75.1) 229 (24.9) 1.0 ref. 1.0 ref.
Yes 827 (80.0) 207 (20.0) 0.87 (0.78 to 0.97) 0.93 (0.83 to 1.04)
1 year No 817 (72.9) 304 (27.1) 1.0 ref. 1.0 ref.
Yes 1130 (79.5) 292 (20.5) 0.84 (0.77 to 0.92) 0.90 (0.82 to 0.98)
Risk ratio crude: poisson regression estimates without adjustment. Risk ratio*: poisson regression estimates adjusted for age at diagnosis, gender, alcohol
assumption, pack-years of smoking, body mass index, and baseline outcome values. DAS28 disease activity in 29 joints, VAS visual analog scale
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Table 4 Risk ratios and 95 % confidence intervals for the association between educational level and having outcome measures of
rheumatoid arthritis decrease over the median, or achieve remission
Visits University/college
degree
Outcome values decrease over the median or achieve remission
No Yes Risk ratio crude (95 % CI) Risk ratio* (95 % CI)
DAS28 low disease activity
3 months No 960 (76.4) 297 (23.6) 1.0 ref. 1.0 ref.
Yes 789 (74.8) 266 (25.2) 1.05 (0.95 to 1.16) 1.00 (0.91 to 1.11)
6 months No 737 (78.2) 206 (21.8) 1.0 ref. 1.0 ref.
Yes 801 (77.3) 235 (22.7) 1.02 (0.93 to 1.13) 0.98 (0.88 to 1.09)
1 year No 822 (78.2) 229 (21.8) 1.0 ref. 1.0 ref.
Yes 1160 (75.4) 379 (24.6) 1.07 (0.99 to 1.14) 1.04 (0.97 to 1.13)
DAS28 good response
3 months No 1073 (75.9) 340 (24.1) 1.0 ref. 1.0 ref.
Yes 642 (75.3) 211 (24.7) 1.02 (0.91 to 1.16) 0.98 (0.86 to 1.11)
6 months No 829 (78.1) 233 (21.9) 1.0 ref. 1.0 ref.
Yes 682 (77.8) 195 (22.2) 1.01 (0.90 to 1.14) 0.96 (0.85 to 1.08)
1 year No 964 (78.5) 264 (21.5) 1.0 ref. 1.0 ref.
Yes 960 (75.0) 320 (25.0) 1.10 (1.01 to 1.20) 1.07 (0.98 to 1.17)
DAS28 remission
3 months No 1214 (76.6) 371 (23.4) 1.0 ref. 1.0 ref.
Yes 535 (73.6) 192 (26.4) 1.11 (0.97 to 1.28) 1.11 (0.97 to 1.28)
6 months No 962 (78.3) 267 (21.7) 1.0 ref. 1.0 ref.
Yes 576 (76.8) 174 (23.2) 1.05 (0.92 to 1.20) 1.00 (0.87 to 1.15)
1 year No 1141 (78.2) 318 (21.8) 1.0 ref. 1.0 ref.
Yes 841 (74.4) 290 (25.6) 1.12 (1.02 to 1.24) 1.11 (1.00 to 1.23)
VAS-pain decrease over the median
3 months No 831 (75.3) 273 (24.7) 1.0 ref. 1.0 ref.
Yes 882 (76.8) 266 (23.2) 0.96 (0.87 to 1.06) 1.06 (0.97 to 1.16)
6 months No 750 (77.9) 213 (22.1) 1.0 ref. 1.0 ref.
Yes 763 (78.3) 212 (21.7) 0.99 (0.89 to 1.10) 1.08 (0.98 to 1.19)
1 year No 938 (75.9) 298 (24.1) 1.0 ref. 1.0 ref.
Yes 991 (77.5) 288 (22.5) 0.96 (0.87 to 1.05) 1.05 (0.96 to 1.14)
VAS-pain remission
3 months No 1055 (79.0) 281 (21.0) 1.0 ref. 1.0 ref.
Yes 710 (71.6) 282 (28.4) 1.25 (1.13 to 1.38) 1.13 (1.02 to 1.26)
6 months No 892 (79.7) 227 (20.3) 1.0 ref. 1.0 ref.
Yes 663 (75.4) 216 (24.6) 1.14 (1.02 to 1.28) 1.08 (0.96 to 1.22)
1 year No 1115 (79.0) 297 (21.0) 1.0 ref. 1.0 ref.
Yes 890 (73.6) 319 (26.4) 1.17 (1.07 to 1.28) 1.10 (1.00 to 1.21)
HAQ decrease over the median
3 months No 796 (76.9) 239 (23.1) 1.0 ref. 1.0 ref.
Yes 842 (74.8) 283 (25.2) 1.05 (0.96 to 1.16) 1.11 (1.02 to 1.21)
6 months No 706 (79.0) 188 (21.0) 1.0 ref. 1.0 ref.
Yes 734 (76.6) 224 (23.4) 1.07 (0.96 to 1.18) 1.10 (0.99 to 1.21)
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In addition to all the analyses above, we performed
analysis with extra adjustments for residential area, leis-
ure time physical activity, ACPA-status, treatment at
baseline and study phase, but the results did not alter
substantially and those variables were not kept in the
final analyses. We subsequently carried out the stratified
analysis based on ACPA status, but found no differences
between the two subgroups. We also performed strati-
fied analysis based on treatments, and again found no
differences.
Discussion
In this population-based cohort with early RA, receiving
standard care in a country with a tax-financed, generally
accessible healthcare system, educational background
affect neither the time to diagnosis nor treatment during
the first year. Furthermore, we found that educational
background was not associated with disease activity
(DAS28), but patients with a high educational level had
slightly less pain (VAS-pain) and less functional disabil-
ity (HAQ) at baseline and during the first year receiving
standard care. Consequently, they were also more likely
to achieve pain remission and improvements in func-
tional impairment.
Methodological advantages of our study are its large
sample size, the population-based design, the inclusion
of incident cases, and the extensive information avail-
able. These features made it possible to adjust for several
potential confounders. The general welfare system in
Sweden provides health care to all citizens irrespective
of SES, and the similar symptom duration observed
among patients with different educational levels indi-
cates that the system does not systematically favor earl-
ier attention to individuals with higher education.
Limitations in this study include self-reported educa-
tional background, which could have introduced non-
differential misclassification. This misclassification was
probably small as participants can be expected to re-
member their highest achieved education relatively eas-
ily. Not all EIRA study patients were followed in the
clinical quality register, SRQ. However, the proportion of
university-educated patients in the EIRA study was very
similar (23 % and 20 %) regardless of inclusion in the
SRQ.
To some extent our results confirm previous findings
on the relationship between low SES and worse disease
outcome for some subjective measures [3, 6–11]. How-
ever, unlike previous reports, where fewer outcome
measures were examined, we carried out a comprehen-
sive investigation with both subjective (VAS-pain, VAS-
global, tender joint count, HAQ) and objective outcomes
(swollen joint count and the inflammatory marker, ESR).
We were also able to record prescription of different
anti-rheumatic therapies, and more importantly, ad-
justed for several potential confounders. Interestingly,
we found that levels of education affected neither time
to diagnosis nor prescribed anti-rheumatic treatments,
and that patients with a low educational level were not
inferior in terms of good disease control, but rather the
perceived pain control and functional capacity. These re-
sults are consistent with the long-term results of the
BARFOT study in which 2,800 patients with early RA
were followed up in southern Sweden, with no signifi-
cant effects found between socioeconomic status and
treatment or outcomes (DAS28 and EULAR response)
[16]. In this context it is important to note that the
HAQ questionnaire is a patient-reported outcome
(PROM), thus, it relies exclusively on how the patient
perceives functional impairment [17]. The same applies
for the VAS-pain scale, and it’s possible that educational
background influences how one interprets such mea-
sures. Another possible explanation for the differing re-
sults for the subjective outcomes, or PROMs, could be
unmeasured confounding, e.g., those with a low educa-
tional level might have a more strenuous workload.
Given similar disease activity, patients with physically
demanding jobs may experience and report more pain
and disability in relation to their daily activities. More-
over, although patients with a high educational level had
significantly lower VAS-pain at baseline than patients
with a low educational level, from a statistical point of
view, it should be noted that the difference between 49
and 53 on a 100-mm VAS is probably of limited clinical
relevance. For the HAQ, the median values were 0.88
and 1.00, respectively, and it has previously been
concluded that a difference >0.2 is needed for clinical
relevance [18].
Despite accumulating evidence demonstrating the con-
trasting etiology between the two serologically defined
RA groups based on ACPA [19], our findings showed no
apparent difference in relation to ACPA-status. Several
studies have reported low rates of DMARDs use in RA
Table 4 Risk ratios and 95 % confidence intervals for the association between educational level and having outcome measures of
rheumatoid arthritis decrease over the median, or achieve remission (Continued)
1 year No 872 (78.6) 237 (21.4) 1.0 ref. 1.0 ref.
Yes 949 (74.6) 323 (25.4) 1.11 (1.02 to 1.20) 1.15 (1.06 to 1.25)
Risk ratio crude: poisson regression estimates without adjustment. Risk ratio*: poisson regression estimates adjusted for age at the diagnosis, gender, alcohol
assumption, pack-years of smoking, body mass index, and baseline outcome values. DAS28 disease activity in 29 joints, VAS visual analog scale, HAQ health
assessment questionnaire
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patients in general (30–52 %) [20–24]. One study con-
sisting of 93,143 patients found that individuals with low
income or SES received fewer DMARDs prescriptions
[25]. Our findings in a country with evenly accessible
healthcare, however, did not support that educational
background affects the prescription of treatments, with
similarly high rates of treatment with DMARDs, NSAIDs,
corticosteroids, and biologic agents both at baseline and
during the first year, among patients with distinct educa-
tional backgrounds.
Conclusions
To summarize, we found that higher-educated newly diag-
nosed RA patients had less pain and less functional
impairment at diagnosis and throughout the follow-up
period, although those statistically significant differences
were of limited clinical relevance. Consequently, the pa-
tients with a higher level of education had a slightly
greater chance of achieving pain remission, and improve-
ment in physical function. Our study demonstrates that
RA patients with different educational levels have the
same opportunity to access healthcare including treat-
ment; and that in this context, educational background
has a very limited influence on the disease course.
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